Stem Cell Therapy Global Market Report 2020-30: Covid 19 Growth and Change – Yahoo Finance UK

Bloomberg

(Bloomberg) -- As coronavirus infections in Japan spark increasing alarm, the government has left investors guessing on how much money it will pump into the economy through a third extra budget.This presents a huge challenge for the bond market trying to gauge how much additional debt will be issued in the current fiscal year through March, along with which maturities will be in focus and the likely impact on yields.Key meetings later Thursday between finance ministry officials, investors and primary bond dealers may provide more clarity. Ahead of this, here are some of the main scenarios seen by interest-rate strategists in Tokyo:Record IssuanceThe issuance pipeline for this fiscal year is already at a record 212.3 trillion yen ($2 trillion), which puts pressure on the government to limit additional sales, if it can.But the risk of a big jump is very real if virus infections increase significantly. Tokyo last week raised its Covid-19 alert to the highest of four levels amid a resurgence of the pathogen across the country -- a spike thats come after Prime Minister Yoshihide Suga called on officials to prepare the third extra budget.Wide RangeNew issuance could run from as low as 3 trillion yen to more than 10 trillion yen, according to the most likely scenarios sketched by strategists. The wide range reflects the lack of public guidance on the size of the supplementary budget itself, with the market coalescing around a figure of 10-15 trillion yen while media reports speculate on a number as high as 20 trillion yen and some members of the ruling party call for 30 trillion yen.To keep issuance toward the bottom of the range, the finance ministry could tap reserve funds of about 7 trillion yen that havent been used yet from its first two extra budgets, according to Shinji Ebihara at Barclays Securities.It is also ahead of schedule in refinancing debt that is coming due, providing another source of funds before selling more bonds.Daiwa Securities Co.s Kouji Hamada sees yet another potential scenario -- that the extra budget may bring another 15 trillion yen of issuance but that the calendar for sales remains largely unchanged if the same amount of debt is shelved in the governments fiscal investment and loan program.Further complicating efforts to narrow in on a consensus figure, the extra budget could be rolled out together with plans for next fiscal year, creating a 15-month budget. The budget for the fiscal year ahead is typically compiled and put to Cabinet for approval around mid- to late-December.Yield CurveEbihara is among those who expect a large chunk of the new issuance to come in the form of short-term debt, with three- to six-month bills seen as a likely focus.This would be consistent with Japans second extra budget and the trend in stimulus-related debt issuance globally during the pandemic. And it could also limit the impact on Japans yield curve, which has steepened this year.Yet the uncertainty is still fueling concern about the supply of super-long bonds.Citigroup Global Markets notes that while the government probably has the capacity to limit new issuance, 10-, 20- and 40-year bonds would be candidates for an increase if the third extra budget is unexpectedly large. Yield premiums that the 30-year bonds offer over 10-year notes have almost tripled to more than 60 basis points from a low of 24 basis points in March. Yields on the 40-year bond is hovering near 0.7%, a level last seen in March 2019.More than half of the 128.8 trillion yen issuance plan from the initial budget for the full fiscal year was made up of bonds maturing in 2 to 10 years, while super-long bonds of 20 years and longer and shorter-term bills were both at the low 20 trillion yen level.The first extra budget in April saw super-long debt increase modestly while bills jumped to 37 trillion yen. The second supplementary package in May brought another modest increase in the super-long sector while bills surged to 82.5 trillion yen.The finance ministry will meet bond investors at 10:30 a.m. Tokyo time and primary dealers at 4 p.m.(Adds yield curve widening in 15th paragraph, and timing of meetings in last paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.2020 Bloomberg L.P.

Visit link:
Stem Cell Therapy Global Market Report 2020-30: Covid 19 Growth and Change - Yahoo Finance UK

Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 – PRNewswire

NEW YORK, Nov. 25, 2020 /PRNewswire/ --Amid the COVID-19 crisis, the global market for Cell Harvesting estimated at US$233.2 Million in the year 2020, is projected to reach a revised size of US$381.4 Million by 2027, growing at a CAGR of 7.3% over the period 2020-2027.Manual, one of the segments analyzed in the report, is projected to grow at a 7.9% CAGR to reach US$284.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Automated segment is readjusted to a revised 5.6% CAGR for the next 7-year period. This segment currently accounts for a 28.3% share of the global Cell Harvesting market.

Read the full report: https://www.reportlinker.com/p05798117/?utm_source=PRN

The U.S. Accounts for Over 30.9% of Global Market Size in 2020, While China is Forecast to Grow at a 10.4% CAGR for the Period of 2020-2027

The Cell Harvesting market in the U.S. is estimated at US$72 Million in the year 2020. The country currently accounts for a 30.86% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$34.9 Million in the year 2027 trailing a CAGR of 10.4% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.1% and 7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR while Rest of European market (as defined in the study) will reach US$34.9 Million by the year 2027.We bring years of research experience to this 5th edition of our report. The 226-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05798117/?utm_source=PRN

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1

II. EXECUTIVE SUMMARY II-1

1. MARKET OVERVIEW II-1 Cell Harvesting - A Prelude II-1 Impact of Covid-19 and a Looming Global Recession II-1 With Stem Cells Holding Potential to Emerge as Savior for Healthcare System Struggling with COVID-19 Crisis, Demand for Cell Harvesting to Grow II-1 Select Clinical Trials in Progress for MSCs in the Treatment of COVID-19 II-2 Lack of Antiviral Therapy Brings Spotlight on MSCs as Potential Option to Treat Severe Cases of COVID-19 II-3 Stem Cells Garner Significant Attention amid COVID-19 Crisis II-3 Growing R&D Investments & Rising Incidence of Chronic Diseases to Drive the Global Cell Harvesting Market over the Long-term II-3 US Dominates the Global Market, Asia-Pacific to Experience Lucrative Growth Rate II-4 Biopharmaceutical & Biotechnology Firms to Remain Key End-User II-4 Remarkable Progress in Stem Cell Research Unleashes Unlimited Avenues for Regenerative Medicine and Drug Development II-4 Drug Development II-5 Therapeutic Potential II-5

2. FOCUS ON SELECT PLAYERS II-6 Recent Market Activity II-7 Innovations and Advancements II-7

3. MARKET TRENDS & DRIVERS II-8 Development of Regenerative Medicine Accelerates Demand for Cell Harvesting II-8 The Use of Mesenchymal Stem Cells in Regenerative Medicine to Drive the Cell Harvesting Market II-8 Rise in Volume of Orthopedic Procedures Boosts Prospects for Stem Cell, Driving the Cell Harvesting II-9 Exhibit 1: Global Orthopedic Surgical Procedure Volume (2010- 2020) (in Million) II-11 Increasing Demand for Stem Cell Based Bone Grafts: Promising Growth Ahead for Cell Harvesting II-11 Spectacular Advances in Stem Cell R&D Open New Horizons for Regenerative Medicine II-12 Exhibit 2: Global Regenerative Medicines Market by Category (2019): Percentage Breakdown for Biomaterials, Stem Cell Therapies and Tissue Engineering II-13 Stem Cell Transplants Drive the Demand for Cell Harvesting II-13 Rise in Number of Hematopoietic Stem Cell Transplantation Procedures Propels Market Expansion II-15 Growing Incidence of Chronic Diseases to Boost the Demand for Cell Harvesting II-16 Exhibit 3: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-17 Exhibit 4: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018 II-18 Exhibit 5: Number of New Cancer Cases and Deaths (in Million) by Region for 2018 II-19 Exhibit 6: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others II-19 Exhibit 7: Rising Diabetes Prevalence Presents Opportunity for Cell Harvesting: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045 II-20 Ageing Demographics to Drive Demand for Stem Cell Banking II-20 Global Aging Population Statistics - Opportunity Indicators II-21 Exhibit 8: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 II-21 Exhibit 9: Life Expectancy for Select Countries in Number of Years: 2019 II-22 High Cell Density as Major Bottleneck Leads to Innovative Cell Harvesting Methods II-22 Advanced Harvesting Systems to Overcome Centrifugation Issues II-23 Sophisticated Filters for Filtration Challenges II-23 Innovations in Closed Systems Boost Efficiency & Productivity of Cell Harvesting II-23 Enhanced Harvesting and Separation of Micro-Carrier Beads II-24

4. GLOBAL MARKET PERSPECTIVE II-25 Table 1: World Current & Future Analysis for Cell Harvesting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-25

Table 2: World Historic Review for Cell Harvesting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-26

Table 3: World 15-Year Perspective for Cell Harvesting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 II-27

Table 4: World Current & Future Analysis for Manual by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-28

Table 5: World Historic Review for Manual by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-29

Table 6: World 15-Year Perspective for Manual by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-30

Table 7: World Current & Future Analysis for Automated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-31

Table 8: World Historic Review for Automated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-32

Table 9: World 15-Year Perspective for Automated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-33

Table 10: World Current & Future Analysis for Peripheral Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-34

Table 11: World Historic Review for Peripheral Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-35

Table 12: World 15-Year Perspective for Peripheral Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-36

Table 13: World Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-37

Table 14: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-38

Table 15: World 15-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-39

Table 16: World Current & Future Analysis for Umbilical Cord by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-40

Table 17: World Historic Review for Umbilical Cord by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-41

Table 18: World 15-Year Perspective for Umbilical Cord by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-42

Table 19: World Current & Future Analysis for Adipose Tissue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-43

Table 20: World Historic Review for Adipose Tissue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-44

Table 21: World 15-Year Perspective for Adipose Tissue by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-45

Table 22: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-46

Table 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-47

Table 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-48

Table 25: World Current & Future Analysis for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-49

Table 26: World Historic Review for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-50

Table 27: World 15-Year Perspective for Biotech & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-51

Table 28: World Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-52

Table 29: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-53

Table 30: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-54

Table 31: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-55

Table 32: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-56

Table 33: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-57

III. MARKET ANALYSIS III-1

GEOGRAPHIC MARKET ANALYSIS III-1

UNITED STATES III-1 Increasing Research on Stem Cells for Treating COVID-19 to drive the Cell Harvesting Market III-1 Rising Investments in Stem Cell-based Research Favors Cell Harvesting Market III-1 Exhibit 10: Stem Cell Research Funding in the US (in US$ Million) for the Years 2011 through 2017 III-2 A Strong Regenerative Medicine Market Drives Cell Harvesting Demand III-2 Arthritis III-3 Exhibit 11: Percentage of Population Diagnosed with Arthritis by Age Group III-3 Rapidly Ageing Population: A Major Driving Demand for Cell Harvesting Market III-4 Exhibit 12: North American Elderly Population by Age Group (1975-2050) III-4 Increasing Incidence of Chronic Diseases Drives Focus onto Cell Harvesting III-5 Exhibit 13: CVD in the US: Cardiovascular Disease* Prevalence in Adults by Gender & Age Group III-5 Rising Cancer Cases Spur Growth in Cell Harvesting Market III-5 Exhibit 14: Estimated Number of New Cancer Cases and Deaths in the US (2019) III-6 Exhibit 15: Estimated New Cases of Blood Cancers in the US (2020) - Lymphoma, Leukemia, Myeloma III-7 Exhibit 16: Estimated New Cases of Leukemia in the US: 2020 III-7 Market Analytics III-8 Table 34: USA Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-8

Table 35: USA Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-9

Table 36: USA 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-10

Table 37: USA Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-11

Table 38: USA Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-12

Table 39: USA 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-13

Table 40: USA Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-14

Table 41: USA Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-15

Table 42: USA 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-16

CANADA III-17 Market Overview III-17 Exhibit 17: Number of New Cancer Cases in Canada: 2019 III-17 Market Analytics III-18 Table 43: Canada Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-18

Table 44: Canada Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-19

Table 45: Canada 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-20

Table 46: Canada Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-21

Table 47: Canada Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-22

Table 48: Canada 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-23

Table 49: Canada Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-24

Table 50: Canada Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-25

Table 51: Canada 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-26

JAPAN III-27 Increasing Demand for Regenerative Medicine in Geriatric Healthcare and Cancer Care to Drive Demand for Cell Harvesting III-27 Exhibit 18: Japanese Population by Age Group (2015 & 2040): Percentage Share Breakdown of Population for 0-14, 15-64 and 65 & Above Age Groups III-27 Exhibit 19: Cancer Related Incidence and Deaths by Site in Japan: 2018 III-28 Market Analytics III-29 Table 52: Japan Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-29

Table 53: Japan Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-30

Table 54: Japan 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-31

Table 55: Japan Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-32

Table 56: Japan Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-33

Table 57: Japan 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-34

Table 58: Japan Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-35

Table 59: Japan Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-36

Table 60: Japan 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-37

CHINA III-38 Rising Incidence of Cancer Drives Cell Harvesting Market III-38 Exhibit 20: Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018 III-38 Market Analytics III-39 Table 61: China Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-39

Table 62: China Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-40

Table 63: China 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-41

Table 64: China Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-42

Table 65: China Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-43

Table 66: China 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-44

Table 67: China Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-45

Table 68: China Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-46

Table 69: China 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-47

EUROPE III-48 Cancer in Europe: Key Statistics III-48 Exhibit 21: Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018 III-48 Ageing Population to Drive Demand for Cell Harvesting Market III-49 Exhibit 22: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15- 64, and 65 & Above III-49 Market Analytics III-50 Table 70: Europe Current & Future Analysis for Cell Harvesting by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 III-50

Table 71: Europe Historic Review for Cell Harvesting by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-51

Table 72: Europe 15-Year Perspective for Cell Harvesting by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 III-52

Table 73: Europe Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-53

Table 74: Europe Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-54

Table 75: Europe 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-55

Table 76: Europe Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-56

Table 77: Europe Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-57

Table 78: Europe 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-58

Table 79: Europe Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-59

Table 80: Europe Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-60

Table 81: Europe 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-61

FRANCE III-62 Table 82: France Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-62

Table 83: France Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-63

Table 84: France 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-64

Table 85: France Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-65

Table 86: France Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-66

Table 87: France 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-67

See the rest here:
Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - PRNewswire

Middle East & Africa Cell Therapy Instruments Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Product ; Cell Type ; Process ;…

NEW YORK, Nov. 25, 2020 /PRNewswire/ -- The Middle East and Africa cell therapy instruments market was valued at US$ 398.23 Million in 2019 and is projected to reach US$ 899.62 Million by 2027; it is expected to grow at a CAGR of 11.0% during the forecast period.

Read the full report: https://www.reportlinker.com/p05989550/?utm_source=PRN

The surge in the number of cell therapy transplantation procedures, growing research and development activities, and rising investments in building production facilities for cell and gene therapy products drive the growth of the Middle East and Africa cell therapy instruments market. However, the low success rate of cell therapies and the high cost of cell-based research is expected to restrain the market growth during the forecast period.

Cell therapy typically involves the administration of somatic cell preparations by injecting or grafting it into the patient's body for the treatment of diseases or traumatic damages.The procedure is used to cure diabetes, neurological disorders, related injuries, several cancer types, bones and joints, and genetic disorders.

Continuous research and development activities have led to unique cell therapeutic instruments for the improvement of immune system and efficient treatment of genetic disorders.Various market players provide several consumables such as reagent kits and enzymes as well as devices, equipment, and software to perform various cell therapy processes.

The cell therapy products are derived from animals or human cells and thus need to be protected from contamination.The instruments used in cell therapies help provide protection against contamination and allow scaling up of transplantation.

Companies such as Hitachi Chemical Advanced Therapeutics Solutions; Corning Incorporated; Thermo Fisher Scientific Inc.; MiltenyiBiotec, LLC; Invetech; and Cytiva (General Electric Company) have introduced various equipment and consumables for the cell therapy procedures.

Various US-based companies have their manufacturing units in the Middle East and African countries; the lockdown imposed in response to the COVID-19 pandemic in multiple countries has affected the supply of instruments in this region. Therefore, many organizations are collaborating with other companies to overcome the adverse effects of the pandemic by using cell therapies for the treatment of COVID 19.

The Middle East and Africa cell therapy instruments market, by product, is segmented into consumables, software, equipment, and systems.The consumables segment held the largest share of the market in 2019 and is expected to register the highest CAGR during the forecast period.

On the basis of cell type, the cell therapy instruments market is segmented into animal cells and human cells. The human cells segment held a larger share of the market in 2019 and is estimated to register a higher CAGR during the forecast period.

On the basis of process, the Middle East and Africa cell therapy instruments market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control.The cell processing segment held the largest share of the market in 2019 and is estimated to register the highest CAGR during the forecast period.

The Middle East and Africa cell therapy instruments market, based on end user, is segmented into life science research companies, research institutes, and other end users. The life science research companies segment accounted for the largest share of the market in 2019 and is anticipated to register the highest CAGR during the forecast period.

A few of the major primary and secondary sources associated with this report on the Middle East and Africa cell therapy instruments market are National Center for Biotechnology Information (NCBI); World Health Organization (WHO); Abu Dhabi Stem Cell Center(ADSCC); South African Stem Cell Institute (SASCI); and Global Institute of Stem Cell Therapy and Research (GIOSTAR).

Read the full report: https://www.reportlinker.com/p05989550/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Read the original post:
Middle East & Africa Cell Therapy Instruments Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Cell Type ; Process ;...

Global Stem Cell Banking Market to Get Expansion admist COVID 19, Scope With Advanced Technologies Top Key Players and Forecast 2020-2027 – The…

Databridgemarketresearch.com Present Global Stem Cell Banking Market Industry Trends and Forecast to 2027 new report to its research database. The report spread No of pages: 350 No of Figures: 60 No of Tables: 220 in it. This Global Stem Cell Banking Market report takes into consideration diverse segments of the market analysis that todays business ask for. The Global Stem Cell Banking Market report provides estimations of CAGR values, market drivers and market restraints about the industry which are helpful for the businesses in deciding upon numerous strategies. The base year for calculation in the report is taken as 2017 whereas the historic year is 2016 which will tell you how the Global Stem Cell Banking Market is going to perform in the forecast years by informing you what the market definition, classifications, applications, and engagements are. The report helps you to be there on the right track by making you focus on the data and realities of the industry.

The research studies of this Global Stem Cell Banking Market report helps to evaluate several important parameters that can be mentioned as investment in a rising market, success of a new product, and expansion of market share. Market estimations along with the statistical nuances included in this market report give an insightful view of the market. The market analysis serves present as well as future aspects of the market primarily depending upon factors on which the companies contribute in the market growth, crucial trends and segmentation analysis. This Global Stem Cell Banking Market research report also gives widespread study about different market segments and regions.

Global stem cell banking market is set to witness a substantial CAGR of 11.03% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. The increased market growth can be identified by the increasing procedures of hematopoietic stem cell transplantation (HSCT), emerging technologies for stem cell processing, storage and preservation. Increasing birth rates, awareness of stem cell therapies and higher treatment done viva stem cell technology.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-banking-market&pm

Competitive Analysis:

Global stem cell banking market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of inflammatory disease drug delivery market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors:

Few of the major competitors currently working in global inflammatory disease drug delivery market are: NSPERITE N.V, Caladrius, ViaCord, CBR Systems, Inc, SMART CELLS PLUS, LifeCell International, Global Cord Blood Corporation, Cryo-Cell International, Inc., StemCyte India Therapeutics Pvt. Ltd, Cordvida, ViaCord, Cryoviva India, Vita34 AG, CryoHoldco, PromoCell GmbH, Celgene Corporation, BIOTIME, Inc., BrainStorm Cell Therapeutics and others

Market Definition:Global Stem Cell Banking Market

Stem cells are cells which have self-renewing abilities and segregation into numerous cell lineages. Stem cells are found in all human beings from an early stage to the end stage. The stem cell banking process includes the storage of stem cells from different sources and they are being used for research and clinical purposes. The goal of stem cell banking is that if any persons tissue is badly damaged the stem cell therapy is the cure for that. Skin transplants, brain cell transplantations are some of the treatments which are cured by stem cell technique.

Cord Stem Cell Banking MarketDevelopment and Acquisitions in 2019

In September 2019, a notable acquisition was witnessed between CBR and Natera. This merger will develop the new chances of growth in the cord stem blood banking by empowering the Nateras Evercord branch for storing and preserving cord blood. The advancement will focus upon research and development of the therapeutic outcomes, biogenetics experiment, and their commercialization among the global pharma and health sector.

Cord Stem Cell Banking MarketScope

Cord Stem Cell Banking Marketis segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of the cord stem cell banking marketis further analyzed based on maximum granularity into further segmentation. On the basis of storage type, the market is segmented into private banking, public banking. On the basis of product type, the market is bifurcated into cord blood, cord blood & cord tissue. On the basis of services type, the market is segmented into collection & transportation, processing, analysis, storage. On the basis of source, market is bifurcated into umbilical cord blood, bone marrow, peripheral blood stem, menstrual blood. On the basis of indication, the market is fragmented into cerebral palsy, thalassemia, leukemia, diabetes, autism.

Cord stem cell trading is nothing but the banking of the vinculum plasma cell enclosed in the placenta and umbilical muscle of an infant. This ligament plasma comprises the stem blocks which can be employed in the forthcoming time to tackle illnesses such as autoimmune diseases, leukemia, inherited metabolic disorders, and thalassemia and many others.

Market Drivers

Increasing rate of diseases such as cancers, skin diseases and others Public awareness associated to the therapeutic prospective of stem cells Growing number of hematopoietic stem cell transplantations (HSCTs) Increasing birth rate worldwide

Market Restraint

High operating cost for the therapy is one reason which hinders the market Intense competition among the stem cell companies Sometimes the changes are made from government such as legal regulations

Key Pointers Covered in the Cord Stem Cell Banking MarketIndustry Trends and Forecast to 2026

Market Size Market New Sales Volumes Market Replacement Sales Volumes Market Installed Base Market By Brands Market Procedure Volumes Market Product Price Analysis Market Healthcare Outcomes Market Cost of Care Analysis Market Regulatory Framework and Changes Market Prices and Reimbursement Analysis Market Shares in Different Regions Recent Developments for Market Competitors Market Upcoming Applications Market Innovators Study

Key Developments in the Market:

In August, 2019, Bayer bought BlueRock for USD 600 million to become the leader in stem cell therapies. Bayer is paying USD 600 million for getting full control of cell therapy developer BlueRock Therapeutics, promising new medical area to revive its drug development pipeline and evolving engineered cell therapies in the fields of immunology, cardiology and neurology, using a registered induced pluripotent stem cell (iPSC) platform. In August 2018, LifeCell acquired Fetomed Laboratories, a provider of clinical diagnostics services. The acquisition is for enhancement in mother & baby diagnostic services that strongly complements stem cell banking business. This acquisition was funded by the internal accruals which is aimed to be the Indias largest mother & baby preventive healthcare organization.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-banking-market&pm

Research objectives

To perceive the most influencing pivoting and hindering forces in Cord Stem Cell Banking Market and its footprint in the international market. Learn about the market policies that are being endorsed by ruling respective organizations. To gain a perceptive survey of the market and have an extensive interpretation of the Cord Stem Cell Banking Market and its materialistic landscape. To understand the structure of Cord Stem Cell Banking Market by identifying its various sub segments. Focuses on the key global Cord Stem Cell Banking Market players, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). To project the consumption of Cord Stem Cell Banking Market submarkets, with respect to key regions (along with their respective key countries). To strategically profile the key players and comprehensively analyze their growth strategies To analyze the Cord Stem Cell Banking Market with respect to individual growth trends, future prospects, and their contribution to the total market.

Customization of the Report:

All segmentation provided above in this report is represented at country level All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Original post:
Global Stem Cell Banking Market to Get Expansion admist COVID 19, Scope With Advanced Technologies Top Key Players and Forecast 2020-2027 - The...

New study on CRISPR: the stake of unintended consequences in embryos – BioNews

23 November 2020

A recent paper published in the journalCell revealed the cautionary finding that unwanted changes are introduced after modifying genesin human embryos with CRISPR/Cas9. The study, led by Dr Dietrich Egli, assistant professor of developmental cell biology at Columbia University Vagelos College of Physicians and Surgeons, tested theeffects of CRISPR-based genome editingon embryos carrying a mutationin a gene called EYS (eyes shut homolog) which could lead to hereditary blindness. It shows that applying this potent approachto repair a blindness-causing gene in the formation of an early embryo discards the whole chromosome, or a considerable portion of it, and that the loss of the chromosome is widespread.

CRISPR-based genome editing has revolutionised molecular life sciences. It allows scientists to perform accurate modifications in the genomes of living tissues and may lead to new medical therapies such as innovative cancer treatments and curing hereditary illnesses. In October 2020, CRISPR discoverers (Professors Emmanuelle Charpentier of Max Planck Institute for Infection Biology, Germany, and Jennifer Doudna of University of California, Berkeley) were jointly awarded the Nobel Prize in chemistry.

However, like most innovative techniques, there are currently technical challenges. For example, it is possible to produce so-called off-target effects, where edits are performed in the wrong area. Researchers are still unsure as to how this might affect patients. Another concern is mosaicism, where some cells carry the edit but others do not. Such changes performed to sperm,egg and embryos can be passed to subsequent generations. In the second international summit on human genome editing, there was broad agreement among the experts in attendance that these risks are high.

Despite these serious concerns, in December 2018, Dr He Jiankui shocked the world by announcing that the first babies had been born with altered genomes (see BioNews 978). His work has attracted a backlash from the international scientific community and various governments. Dr He has been sentenced to three years in jail and fined for performing 'illegal medical practices'.

The new research indicates that CRISPR genome editing is currently not ready for clinical application to correct mutations in this early phase of human development. These findings should deter premature clinical use of genome editing on embryos. Thus, using CRISPR to edit the genomes of embryos is a far-off reality.

Due to the serious ethical concerns, the US government does not allow the use of federal funds to perform research on human embryos. The experiment was sponsored by private funding (the New York Stem Cell Foundation and the Russell Berrie Foundation programme). In Australia, section 15 of the Prohibition of Human Cloning for Reproduction Act 2002 prohibits a person from altering the genome of a human embryo in such a manner that the change is heritable by its descendantsandthe person intended this to be so. The penaltyfor this offence is imprisonment for 15 years.

We need to guide responsible and ethical research to achieve safe and effective use. In November 2020, the members of the International Society for Stem Cell Research (ISSCR) task force were charged with revising the2016 ISSCR Guidelines (the Guidelines for Stem Cell Research and Clinical Translation). The ISSCR is the largest stem cell organisation in the world. As a contribution to the developing and controversial stem cell field, this organisation has developed guidelines that address the global diversity of ethical, legal, ethical, cultural and political perspectives related to stem cell research and its translation to clinical application. The guidelines underscore widely shared principles that call for rigour, oversight and transparency. Strict adherence to these principles assures that such cutting-edge research is being conducted with integrity and that innovative medical treatments are evidence-based. Recent advances in this field include innovations in genome editing, organoidsand chimeras. Responding to these various developments in science, the updates will encompass a broader and more expansive scope of research and clinical endeavour, imposing rigour on every stage of the study, addressing the cost of regenerative medicine products and stressing the need for precise and effective public communication.

The persuasive ISSCR Guidelines have been adopted by some scientists, clinicians and institutions around the world. While mere guidelines do not supersede local laws, they could inform the interpretation as well as the development of local laws and provide guidance for research practices not covered by the law. As these guidelines will be updated soon, it is important that they do not encourage the clinical application of the CRISPR approach on genome-editing human embryos for the time being.

Read the original:
New study on CRISPR: the stake of unintended consequences in embryos - BioNews

The Stem Cell Characterization and Analysis Tools Market to grow incomparably in the next decade – The Market Feed

Stem cell characterization is the study of tissue-specific differentiation. Thera are various type of stem cell such as embryonic stem cell, epithelial stem cell and others. Further, various techniques are used to characterized stem cells such as immunological techniques, used for depiction of different population of stem cells. These techniques are generally based on immunochemistry using staining technique or florescent microscopy. Besides, stem cells characterization and analysis tools are used against target chronic diseases. In 2014, the San Diego (UCSD) Health System and Sanford Stem Cell Clinical Center at the University of California announced the launch of a clinical trial, in order to assess the safety of neural stem cellbased therapy in patients with chronic spinal cord injury.

The factors driving the growth of stem cell characterization and analysis tools market due to increasing chronic disorders such as cancer, a diabetes and others. In addition, increasing awareness about among people about the therapeutic potency of stem cells characterization in the management of effective diseases is anticipated to increase the demand for stem cell characterization and analysis tools. Further, there are various technologies such as flow cytometry which is used to characterize the cell surface profiling of human-bone marrow and other related purposes are expected to increase the growth of stem cell characterization and analysis tools market. In addition, increasing investment by private and public organization for research activities are likely to supplement the market growth in near future.

On the other hand, the unclear guidelines and the technical limitation for the development of the product are expected to hamper the growth of stem cell characterization and analysis tools market.

Rapid increase in corona virus all around the world is expected to hamper the growth of stem cell characterization and analysis tools market. The virus outburst has become one of the threats to the global economy and financial markets. The impact has made immense decrease in revenue generation in the field of all healthcare industry growth for the market in terms of compatibility and it has led in huge financial losses and human life which has hit very hard to the core of developing as well as emerging economies in healthcare sector. It further anticipated that such gloomy epidemiological pandemic environment is going to remain in next for at least some months, and this is going to also affect the life-science market which also include the market of stem cell characterization and analysis tools market.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/31444

Based on the Products and Service Type, stem cell characterization and analysis tools market are segmented into:

Based on the Technology, stem cell characterization and analysis tools market are segmented into:

Based on the Applications, stem cell characterization and analysis tools market are segmented into:

Based on the End User, stem cell characterization and analysis tools market are segmented into:

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/31444

Based on the segmentation, human embryonic stem cell is expected to dominate the market due to their indefinite life span and higher totipotency as compared to other stem cells. Further, on the basis of technology segmentations, cell production is anticipated to increase the demand for stem cell characterization and analysis tools due to their emerging applications for stem cells in drug testing in the management of the effective diseases. Furthermore, on the basis of application segmentations, oncology is expected to show significant growth rate due to increase in the number of pipelines products for the treatment of cancers or tumors. Based on the end user, pharmaceutical and biotechnology companies are expected to dominate the market due to rising global awareness about the therapeutics research activities.

Geographically, the global stem cell characterization and analysis tools market is segmented into regions such as Latin America, Europe, North America, South Asia, East Asia Middle East & Africa and Oceania. North America is projected to emerge as prominent market in the global stem cell characterization and analysis tools market due to growing cases of target chronic diseases and increasing investments for research activities. Europe is the second leading region to dominate the market due to technological advancement and also surge in therapeutic activities, funded by government across the world. Asia-pacific is likely to witness maximum growth in near future due to increasing disposable income and with the development of infrastructure.

Some of the major key players competing in the global stem cell characterization and analysis tools market are Osiris Therapeutics, Inc., Caladrius Biosciences, Inc., U.S. Stem Cell, Inc., Astellas Pharma Inc., TEMCELL Technologies Inc., BioTime Inc., Cellular Engineering Technologies Inc., Cytori Therapeutics, Inc., and BrainStorm Cell Therapeutics Inc.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/31444

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved Beg Persistence Market Research Address 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Sales[emailprotected] Websitehttps://www.persistencemarketresearch.com

View post:
The Stem Cell Characterization and Analysis Tools Market to grow incomparably in the next decade - The Market Feed

New solution to kill coronavirus on common surfaces in seconds – University of California

UCLA engineers and scientists have demonstrated that treatments with near-room-temperature, cold atmospheric plasma can kill the coronavirus present on a variety of surfaces in as little as 30 seconds.

Astudy detailing the research, which was published this month in the journal Physics of Fluids, is the first time cold plasma has been shown to effectively and quickly disinfect surfaces contaminated with the SARS-CoV-2 virus that causes COVID-19.

The novel coronavirus can remain infectious for tens of hours on surfaces so the advance is a major breakthrough that may help slow the spread of virus.

This is a really exciting result, showing the potential of cold atmospheric plasma as a safe and effective way to fight transmission of the virus by killing it on a wide range of surfaces, said study leader Richard Wirz, professor of mechanical and aerospace engineering at the UCLA Samueli School of Engineering.

Plasma, not to be confused with blood plasma, is an electrically charged gas known as the fourth state of matter (solid, liquid and gas being the others), with electrons and charged ions accounting for its main makeup.

The researchers created the plasma by subjecting air and argon gas a common, non-toxic gas to a strong electric field across electrodes inside a spray jet built by a 3D printer. The resulting ionized, atmospheric cold plasma remains stable at room temperatures.

The team used the jet to spray plastic, metal, cardboard and leather surfaces laced with SARS-CoV-2 cultures. The jet ionized the surrounding air, turning it into cold atmospheric plasma and killing most of the virus after 30 seconds. The team saw similar results with cotton from facemasks. Leather from a basketball, football and baseball was included to test effectiveness in disinfecting sports equipment and to simulate the rough and wrinkled surface of skin.

Cold plasma has previously been shown in research studies to be effective incancer treatment, wound healing, dental-instrument disinfection and other applications.

An important advantage of plasma is that it can be safely used on a variety of surfaces without damaging them, while treatments with chemicals and UV light cannot be used effectively on porous surfaces like cardboard and skin without damage.

Another advantage is an estimated lower cost for supplies compared to standard chemical sanitizers. The researchers are working with campus units at UCLA to further test the system.

This eco-friendly, innovative technology could be implemented to prevent the transmission of SARS-CoV-2 in hospitals, transportation and sports settings, said study co-author Vaithi Arumugaswami, an associate professor of molecular and medical pharmacology at theDavid Geffen School of Medicine at UCLA.

According to Wirz, cold plasma may even be a potential candidate, pending further study, to kill the coronavirus when it is airborne.

The studys lead author is Zhitong Chen, a postdoctoral scholar inWirzs research group, which performs a wide range of plasma-based research, from propulsion to fusion materials.

UCLA staff research associate Gustavo Garcia, a member ofArumugaswamis research group, is also an author on the paper.

The research was supported in part by the Air Force Office of Scientific Research, with additional support from the Geffen School of Medicine and the Broad Stem Cell Research Institute.

The researchers have also created a UCLA-based startup, uPlasma, to further explore the potential of the technology.

Go here to read the rest:
New solution to kill coronavirus on common surfaces in seconds - University of California

Agricultural Equipment Market to Witness Robust Expansion Throughout the Forecast Period 2027 – re:Jerusalem

The globalAgricultural Equipment Marketis projected to grow with a striking growth rate of 4.15 % over the forecast period 2020-2027, divulges the latest research report presented by Big Market Research.

Top Countries Data Covered in This Report are: United States, Canada, Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Columbia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa,

The report mainly studies the size, recent trends and development status of the Agricultural Equipment market, as well as investment opportunities, market dynamics (such as driving factors, restraining factors), and industry news (like mergers, acquisitions, and investments). Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Agricultural Equipment market.

Global Agricultural Equipment Industry 2020 Market Research Report is provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Global Agricultural Equipment market competition by TOP MANUFACTURERS, with production, price, revenue (value) and each manufacturer includingJohn Deere,AGCO Corporation,CNH Industrial,CLAAS,Kubota,Mahindra & Mahindra,SPF Group,J C Bamford Excavators,Iseki Co., Ltd. ,Deutz-Fahr Group S.p.A

Request for a sample copy of this report @https://www.bigmarketresearch.com/request-sample/4060835?utm_source=SHASHI&utm_medium=RS

By Type: Tractors Harvesters Soil Preparation & Cultivation Irrigation & Crop Processing Agriculture Spraying Equipment Hay & Forage Machines Others By Automation: Manual Semi-Automatic Automatic Equipment

Global Agricultural Equipment Market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Global Agricultural Equipment market development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

With tables and figures helping analyze worldwide Global Agricultural Equipment market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The information for each competitor includes:

Company Profile

Main Business Information

SWOT Analysis

Sales, Revenue, Price and Gross Margin

Market Share

Reasons to Purchase this Report:

Analyzing the outlook of the market with the recent trends and SWOT analysis

Market dynamics scenario, along with growth opportunities of the market in the years to come

Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects

Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

Market value (USD Million) and volume (Units Million) data for each segment and sub-segment

Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Avail the Discount on this Report @https://www.bigmarketresearch.com/request-for-discount/4060835?utm_source=SHASHI&utm_medium=RS

Table of Contents

Chapter 1. Global Agricultural Equipment Market Definition and Scope

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Global Agricultural Equipment Market Dynamics

Chapter 5. Agricultural Equipment Market, by Component

Chapter 6. Global Agricultural Equipment Market, by Services

Chapter 7. Global Agricultural Equipment Market, by Organization Size

Chapter 8. Agricultural Equipment Market, by Vertical

Chapter 9. Agricultural Equipment Market, by Regional Analysis

Chapter 10. Competitive Intelligence

Related Report:

Global Cell Expansion Market Size study with COVID-19 Impact, by Product (Consumables, Instruments, Bioreactors and Automated Cell Expansion Systems), by Cell Type (Human Cells and Animal Cells), by Application (Regenerative Medicine and Stem Cell Research, Cancer and Cell-based Research and Others), by End User (Research Institutes, Biotechnology and Biopharmaceutical Companies, Cell Banks and Others) and Regional Forecasts 2020-2027

https://www.bigmarketresearch.com/report/3933633/global-cell-expansion-market?utm_source=SHASHI&utm_medium=RR

Global Renewable Methanol Market Size study, by Feedstock (Agricultural Waste, Forestry Residues, Municipal Solid Waste, Co2 Emissions, Others), by Application (Formaldehyde, Dimethyl Ether, Gasoline, Solvents, Others), by End-User (Chemicals, Transportation, Power Generation, Others) and Regional Forecasts 2020-2027

https://www.bigmarketresearch.com/report/3974584/global-renewable-methanol-market?utm_source=SHASHI&utm_medium=RR

About Us:

Big Market Research has a range of research reports from various publishers across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

We are instrumental in providing quantitative and qualitative insights on your area of interest by bringing reports from various publishers in one place to save your time and money. A lot of organizations across the world are gaining profits and great benefits from information gained through reports sourced by us.

Contact Us:

Mr. Abhishek Paliwal

5933 NE Win Sivers Drive, #205, Portland,

OR 97220 United States

Call answer Direct:+1-971-202-1575

Call answer Toll-Free:+1-800-910-6452

Emailhelp@bigmarketresearch.com

Originally posted here:
Agricultural Equipment Market to Witness Robust Expansion Throughout the Forecast Period 2027 - re:Jerusalem

Animal Stem Cell Therapy Market Projected to Witness Vigorous Expansion by 2027 – re:Jerusalem

Big Market Research, one of the worlds prominent market research firms has released a new report on GlobalAnimal Stem Cell Therapy Market, The report expertise includes assessing new opportunities & sizing, identifying and evaluating complex global value chains (including key drivers, restraints and winning strategies). The report will help the vendor to strategize its positioning in the Animal Stem Cell Therapy Market projects around the globe. The detailed competitor profiling helped identify and understand the key strategies and growth drivers of its competitors. The report includes detailed profile of key competitors, pre/post launch surveys, go-to-market research, supplier selection surveys, industry demand/pain point surveys, pricing analysis, product testing, effectiveness studies, and product positioning studies.

The Animal Stem Cell Therapy Market research report includes:

The Animal Stem Cell Therapy Market report explore:

The Animal Stem Cell Therapy Market includes identification of important potential market demand, expected sale of these devices in the next 5 years, various price and demand sensitive scenarios were built to ascertain on the profitability of investing, customer analysis, and future price analysis.

Ask pdf sample copy of this premium research on Animal Stem Cell Therapy with Figures, Graphs and Tocs:https://www.bigmarketresearch.com/request-sample/4083483?utm_source=PRL&utm_medium=MWA

The Animal Stem Cell Therapy Market is also characterized by a highly complex value chain involving product manufacturers, material suppliers, technology developers, and manufacturing equipment developers. Partnerships between research organizations and the industry players help in streamlining the path from the lab to commercialization. In order to also leverage the first mover benefit, companies need to collaborate with each other so as to develop products and technologies that are unique, innovative and cost effective.

Several existing Animal Stem Cell Therapy Industry manufacturers, new start-ups as well as research organizations and universities are constantly coming up with innovative ideas. The Animal Stem Cell Therapy Market is expected to grow exponentially over the next five years with the emergence of new applications and cost competitive products.

Market players have been discussed and profiles of leading players including Top Key Companies: Medivet Biologics LLC VETSTEM BIOPHARMA J-ARM U.S. Stem Cell, Inc VetCell Therapeutics Celavet Inc. Magellan Stem Cells Kintaro Cells Power Animal Stem Care Animal Cell Therapies Cell Therapy Sciences Animacel

Animal Stem Cell Therapy Market By Product Type 2019-2025: Dogs Horses Others

Based on type, the global market is segmented into the following sub-markets with annual revenue for 2015-2025 (historical and forecast) included in each section.

Animal Stem Cell Therapy Market By Application 2019-2025: Veterinary Hospitals Research Organizations

Based on application, the global market is segmented into the following sub-markets with annual revenue for 2019-2025 (historical and forecast) included in each section.

Talk to our Analyst / Ask for a discount on Animal Stem Cell Therapy:https://www.bigmarketresearch.com/request-for-discount/4083483?utm_source=PRL&utm_medium=MWA

The comprehensive competitive landscape section of the report contains detailed analysis of the trends in mergers and acquisitions, agreements and partnerships, new product launches and so on in the Animal Stem Cell Therapy Market. This information will be very useful for existing players as well as new entrants in any market.

Geographically,Animal Stem Cell TherapyMarket is further analyzed into regions and country level analysis:North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Animal Stem Cell Therapy market forecast of till 2025. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, and growth drivers of by analyzing the historical overall data of the considered market segments.

You May Also Like Our Other Top Trending Reports:

Read More:https://www.bigmarketresearch.com/report/3767216/global-x-ray-security-scanner-sale-insights-market?utm_source=PRL&utm_medium=MWA

About Us:

Big Market Researchhas a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us: Mr. Abhishek Paliwal 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States Direct:+1-971-202-1575 Toll Free:+1-800-910-6452 E-mail:help@bigmarketresearch.com

Visit link:
Animal Stem Cell Therapy Market Projected to Witness Vigorous Expansion by 2027 - re:Jerusalem

Rheumatoid Arthritis Stem Cell Therapy Market to Ride on Increased Prevalence of Rheumatoid Arthritis – TMR Research Blog

Rheumatoid arthritis refers to an inflammatory disease of the supportive tissues of the body and the condition generally affects fingers and toes of human beings. This inflammation is caused by an abnormal response of the body to the normal functioning tissues. This leads to acute pain and malformed joints. Novel cells that are produced by regenerative centers of the body are called stem cells. These cells can be changed into any other type of cell in the body with just the right kind of stimulant. The growth of the global rheumatoid arthritis stem cell therapy market is likely to observe growth in its ability to demonstrate profound healing activity. It also helps in checking the arthritic condition. In addition to that, this therapy is capable of regenerating and reversing joint tissue in many cases, which is likely to pave way for rapid growth of the global rheumatoid arthritis stem cell therapy market in the years to come.

Get SampleCopy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6864

Ability to Diminish Pain and Inflammation to Bolster Demand in the Market

In present times, human umbilical cord tissue (allogeneic mesenchymal stem cells), fat-derived or adipose stem cells, and bone marrow transplant are utilized for the purpose of the rheumatoid arthritis stem cell therapy. As the condition becomes worse, the body starts autoimmune response and keeps on attacking the cells of the body. The global rheumatoid arthritis stem cell therapy market is estimated to gather momentum from its growing importance and popularity in specialty clinics, ambulatory surgical centers, and hospitals. This therapy comes with the excellent healing capabilities that can treat the entire system causing inflammation and joint pain.

Extensive growth opportunities of the global rheumatoid arthritis stem cell therapy market are likely to be influenced by the multiple benefits offered by this therapy. However, this therapy comes with its own share of disadvantages as well and is not an infallible method for healing arthritis. All though, this therapy is capable of assisting in the stabilization of the body immune system and diminish inflammation.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6864

Like Loading...

As Head of Marketing at TMR Research, Rohit brings to the table over a decade of experience in market research and Internet marketing. His dedication, perseverance, and passion for perfection have enabled him to achieve immense success in his field. Rohit is an expert at formulating new business plans and strategies to help boost web traffic. His interests lie in writing news articles on technology,healthcare and business. View all posts by Rohit Bhisey

More:
Rheumatoid Arthritis Stem Cell Therapy Market to Ride on Increased Prevalence of Rheumatoid Arthritis - TMR Research Blog